10-K · February 26, 2026
Puma reported a Q4 2025 beat with revenue of $75.5M and EPS of $0.29, supporting a trailing twelve-month revenue roughly flat vs. 2024 (~$227M in 2025 vs. ~$231M in 2024). The business remains single-product (NERLYNX)…
Earnings analysis · 10-Q
PBYI earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Puma Biotechnology reported Q1 2026 results with revenue of $44.8 million, exceeding estimates of $41.4 million, while EPS loss of -$0.04 surpassed expectations of -$0.14. Although total revenue decreased year-over-year…
Read full summary
Puma Biotechnology reported Q1 2026 results with revenue of $44.8 million, exceeding estimates of $41.4 million, while EPS loss of -$0.04 surpassed expectations of -$0.14. Although total revenue decreased year-over-year from $46.0 million in Q1 2025, management raised full-year revenue guidance to $222-$229 million from $214-$221 million, driven by strong demand for NERLYNX.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.04
What stood out
-
Revenue Beat Expectations
Actual revenue was $44.8 million, outpacing estimates of $41.4 million.
-
EPS Surprise
Reported EPS loss of -$0.04 compared to estimates of -$0.14.
-
Improved Cash Flow from Operations
Operating cash flow was $15.4 million, significantly up from $3.6 million in Q1 2025.
-
Strong Cost Control
Operating expenses managed with SG&A increasing only by 4.7% to $18.4 million.
-
Increase in Cash Reserves
Cash and cash equivalents rose to $36.2 million from $29.6 million at year-end.
-
Raised FY 2026 Revenue Guidance
Management updated guidance to $222-$229 million from $214-$221 million.
What to watch
-
Increased R&D Expenses
R&D expenses rose to $19.8 million, a 42.8% increase from $13.9 million in Q1 2025.
-
Decreased Total Revenue YoY
Total revenue decreased from $46 million in Q1 2025 to $44.8 million.
-
Ongoing Clinical Development Risks
Continued reliance on alisertib's development success poses significant operational risks.
Management's outlook
Management raised FY 2026 revenue guidance to $222-$229 million based on product demand.
Earlier filings 4
10-Q · November 6, 2025
Puma reported Q3 2025 total revenue of $54,475,000 and GAAP net income of $8,844,000 (diluted EPS $0.17). Revenue was up modestly versus the prior quarter but materially lower year-over-year due to a sharp drop in…
10-Q · May 8, 2025
Puma reported Q1 2025 revenue of $46,007,000 (up $2,241,000 or 5.1% vs Q1 2024) and GAAP net income of $2,974,000 (EPS $0.06), a turnaround from a net loss of $(4,815,000) (EPS $(0.10)) in Q1 2024. Gross margin remained…
10-Q · November 7, 2024
Puma reported a strong Q3: total revenue of $80.542M (up from $56.116M YoY) and net income of $20.317M (diluted EPS $0.41 vs $0.12 YoY). Operating profit expanded to $22.079M (27.4% margin) despite a meaningful…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.